Company
Medigen Vaccine Biologics Corp
Headquarters: Taipei, Taiwan
Market Cap
TW$23.16 Billion
TWD as of Jan. 1, 2024
US$754.7 Million
Medigen Vaccine Biologics Corp Categories
Taiwan Healthcare BiotechnologyTaiwan Healthcare Taiwan Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Taipei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Medigen Vaccine Biologics Corp has the following listings and related stock indices.
Stock: TWSE: 6547 wb_incandescent